APA (7th ed.) Citation

RM, W., AL, B., SW, G., J, W., BL, F., D, D., . . . AA, S. (2026). A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 36(6), 102856. https://doi.org/10.1016/j.ijgc.2025.102856

Chicago Style (17th ed.) Citation

RM, Wenham, et al. "A Phase 2 Study of Pembrolizumab and Weekly Paclitaxel for Platinum-resistant Epithelial Ovarian Cancer." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 36, no. 6 (2026): 102856. https://doi.org/10.1016/j.ijgc.2025.102856.

MLA (9th ed.) Citation

RM, Wenham, et al. "A Phase 2 Study of Pembrolizumab and Weekly Paclitaxel for Platinum-resistant Epithelial Ovarian Cancer." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, vol. 36, no. 6, 2026, p. 102856, https://doi.org/10.1016/j.ijgc.2025.102856.